Contra-indicated in patients with narcolepsy.
- Trade Name: Belsomra (Merck Sharpe & Dohme)
- Indications: Insomnia
- Class: Hypnotic, Orexin receptor antagonist
- Half-life: 10–22 hours
- FDA Approval Date: 08/13/2014
- Clinically important, potentially hazardous interactions with:
None known
- See adverse reactions attributed to class:
Please login to view the rest of this drug profile.
Page last updated 04/29/2026
